Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether daily use of emtricitabine/tenofovir
disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV
counseling, condoms, and treatment for other sexually transmitted infections (STIs).
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir